title: Long-term outcome in patients treated by intracoronary stenting with ticlopidine and aspirin, and deleterious prognostic role of unstable angina pectoris.
abstract: Compared with stable clinical conditions, unstable angina carries an increased risk of immediate and delayed cardiac adverse events after balloon coronary angioplasty. The influence of stent use in reducing these differences remains unknown. We analyzed the early (30 days) and late outcome of a cohort of 459 consecutive patients who underwent stent placement with ticlopidine and aspirin as antithrombotic regimen according to the presence (group 1, n = 151) or absence (group 2, n = 308) of unstable angina at rest (Braunwald classes II and III). Group 1 patients were older and more likely to be current or former smokers. In group 2, prior myocardial infarction was more frequent. Procedural, in-hospital results, and early outcome were similar in the 2 groups. However, over the long term, the incidence of myocardial infarction (11% vs 6%, p <0.04), target lesion revascularization (19% vs 13%, p <0.04), or any revascularization (30% vs 20%, p <0.01) was significantly higher in group 1. Kaplan-Meier probabilities of survival without myocardial infarction (85% vs 91%, p <0.05), survival without revascularization of the target lesion (73% vs 83%, p <0.01), survival without any revascularization (65% vs 77%, p <0.006), and survival without any events (61% vs 73%, p <0.009) were significantly worse in group 1. In addition, Cox multivariate analysis showed that unstable angina at rest was an independent predictor of target lesion revascularization, of survival without any revascularization, and without any events. Thus, unstable angina at rest remains an adverse prognostic indicator in patients treated with intracoronary stents, particularly with regard to subsequent requirement of revascularization procedures and event-free survival.
authors.affiliation: Service de Cardiologie, Hôpitaux de Brabois, Vandoeuvre-lès-Nancy, France. m.angioi@chu-nancy.fr
authors.forename: M
authors.initials: M
authors.lastname: Angioi
authors.forename: N
authors.initials: N
authors.lastname: Danchin
authors.forename: F
authors.initials: F
authors.lastname: Alla
authors.forename: C
authors.initials: C
authors.lastname: Gangloff
authors.forename: H
authors.initials: H
authors.lastname: Sunthorn
authors.forename: R M
authors.initials: RM
authors.lastname: Rodriguez
authors.forename: J P
authors.initials: JP
authors.lastname: Preiss
authors.forename: A
authors.initials: A
authors.lastname: Grentzinger
authors.forename: P
authors.initials: P
authors.lastname: Houplon
authors.forename: Y
authors.initials: Y
authors.lastname: Juillière
authors.forename: F
authors.initials: F
authors.lastname: Cherrier
mesh_terms: D000368:Aged; D000789:Angina, Unstable / Q000188:drug therapy* / Q000401:mortality / Q000628:therapy*; D001241:Aspirin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011379:Prognosis; D015607:Stents; D016019:Survival Analysis; D013988:Ticlopidine / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D013988:Ticlopidine; D001241:Aspirin